Global chemotherapy development for gastric cancer

Kazuto Harada; Dilsa Mizrak Kaya; Yusuke Shimodaira; Jaffer A. Ajani

doi:10.1007/s10120-016-0655-8

Global chemotherapy development for gastric cancer

Kazuto Harada, Dilsa Mizrak Kaya, Yusuke Shimodaira, Jaffer A. Ajani

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

To combat the dismal mortality rates from metastatic gastric adenocarcinoma (GAC), new drugs and treatment strategies are needed. Today, metastatic GAC is predominantly treated by empiric chemotherapy. Combination of two cytotoxic agents has become commonplace in North America, Europe, and Asia. Human epidermal growth factor 2 (HER2) overexpression (protein or gene copy numbers) has resulted in the addition of trastuzumab in the first-line chemotherapy combination in patients whose tumor is HER2 positive. The addition of trastuzumab in this select population has provided a modest survival advantage. In this review we trace the global development of systemic therapy in patients with metastatic GAC and ponder what lies in the future.

Original language	English (US)
Pages (from-to)	92-101
Number of pages	10
Journal	Gastric Cancer
Volume	20
DOIs	https://doi.org/10.1007/s10120-016-0655-8
State	Published - Mar 1 2017

Keywords

Chemotherapy
Gastric adenocarcinoma
Molecularly targeted drug

ASJC Scopus subject areas

Oncology
Gastroenterology
Cancer Research

Access to Document

10.1007/s10120-016-0655-8

Cite this

@article{6911dad6b68b4396a2cc8af0271b5d4b,

title = "Global chemotherapy development for gastric cancer",

abstract = "To combat the dismal mortality rates from metastatic gastric adenocarcinoma (GAC), new drugs and treatment strategies are needed. Today, metastatic GAC is predominantly treated by empiric chemotherapy. Combination of two cytotoxic agents has become commonplace in North America, Europe, and Asia. Human epidermal growth factor 2 (HER2) overexpression (protein or gene copy numbers) has resulted in the addition of trastuzumab in the first-line chemotherapy combination in patients whose tumor is HER2 positive. The addition of trastuzumab in this select population has provided a modest survival advantage. In this review we trace the global development of systemic therapy in patients with metastatic GAC and ponder what lies in the future.",

keywords = "Chemotherapy, Gastric adenocarcinoma, Molecularly targeted drug",

author = "Kazuto Harada and {Mizrak Kaya}, Dilsa and Yusuke Shimodaira and Ajani, {Jaffer A.}",

note = "Publisher Copyright: {\textcopyright} 2016, The International Gastric Cancer Association and The Japanese Gastric Cancer Association.",

year = "2017",

month = mar,

day = "1",

doi = "10.1007/s10120-016-0655-8",

language = "English (US)",

volume = "20",

pages = "92--101",

journal = "Gastric Cancer",

issn = "1436-3291",

publisher = "Springer Japan",

}

TY - JOUR

T1 - Global chemotherapy development for gastric cancer

AU - Harada, Kazuto

AU - Mizrak Kaya, Dilsa

AU - Shimodaira, Yusuke

AU - Ajani, Jaffer A.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - To combat the dismal mortality rates from metastatic gastric adenocarcinoma (GAC), new drugs and treatment strategies are needed. Today, metastatic GAC is predominantly treated by empiric chemotherapy. Combination of two cytotoxic agents has become commonplace in North America, Europe, and Asia. Human epidermal growth factor 2 (HER2) overexpression (protein or gene copy numbers) has resulted in the addition of trastuzumab in the first-line chemotherapy combination in patients whose tumor is HER2 positive. The addition of trastuzumab in this select population has provided a modest survival advantage. In this review we trace the global development of systemic therapy in patients with metastatic GAC and ponder what lies in the future.

AB - To combat the dismal mortality rates from metastatic gastric adenocarcinoma (GAC), new drugs and treatment strategies are needed. Today, metastatic GAC is predominantly treated by empiric chemotherapy. Combination of two cytotoxic agents has become commonplace in North America, Europe, and Asia. Human epidermal growth factor 2 (HER2) overexpression (protein or gene copy numbers) has resulted in the addition of trastuzumab in the first-line chemotherapy combination in patients whose tumor is HER2 positive. The addition of trastuzumab in this select population has provided a modest survival advantage. In this review we trace the global development of systemic therapy in patients with metastatic GAC and ponder what lies in the future.

KW - Chemotherapy

KW - Gastric adenocarcinoma

KW - Molecularly targeted drug

UR - http://www.scopus.com/inward/record.url?scp=84990929612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990929612&partnerID=8YFLogxK

U2 - 10.1007/s10120-016-0655-8

DO - 10.1007/s10120-016-0655-8

M3 - Article

C2 - 27718136

AN - SCOPUS:84990929612

SN - 1436-3291

VL - 20

SP - 92

EP - 101

JO - Gastric Cancer

JF - Gastric Cancer

ER -

Global chemotherapy development for gastric cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this